BR112018075403A2 - composições para tratar ou prevenir sintomas vasomotores - Google Patents

composições para tratar ou prevenir sintomas vasomotores

Info

Publication number
BR112018075403A2
BR112018075403A2 BR112018075403-0A BR112018075403A BR112018075403A2 BR 112018075403 A2 BR112018075403 A2 BR 112018075403A2 BR 112018075403 A BR112018075403 A BR 112018075403A BR 112018075403 A2 BR112018075403 A2 BR 112018075403A2
Authority
BR
Brazil
Prior art keywords
compositions
treating
vasomotor symptoms
preventing vasomotor
preventing
Prior art date
Application number
BR112018075403-0A
Other languages
English (en)
Inventor
M. PALUMBO Joseph
Original Assignee
Mitsubishi Tanabe Pharma Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corporation filed Critical Mitsubishi Tanabe Pharma Corporation
Publication of BR112018075403A2 publication Critical patent/BR112018075403A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção refere-se a composições e métodos para tratar ou prevenir sintomas vasomotores como ondas calor, compreendendo um antagonista receptor de potencial transitório de melastatina tipo 8 (trpm8) e administrando o antagonista trpm8, respectivamente.
BR112018075403-0A 2016-06-13 2017-06-12 composições para tratar ou prevenir sintomas vasomotores BR112018075403A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662349179P 2016-06-13 2016-06-13
US62/349,179 2016-06-13
PCT/JP2017/021569 WO2017217351A1 (en) 2016-06-13 2017-06-12 Compositions for treating or preventing vasomotor symptoms

Publications (1)

Publication Number Publication Date
BR112018075403A2 true BR112018075403A2 (pt) 2019-03-19

Family

ID=59101629

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018075403-0A BR112018075403A2 (pt) 2016-06-13 2017-06-12 composições para tratar ou prevenir sintomas vasomotores

Country Status (17)

Country Link
US (2) US10993939B2 (pt)
EP (2) EP4140484A1 (pt)
JP (1) JP6943887B2 (pt)
KR (2) KR20230005413A (pt)
CN (4) CN114748624A (pt)
AU (2) AU2017285609B2 (pt)
BR (1) BR112018075403A2 (pt)
CA (1) CA3022808A1 (pt)
CO (1) CO2018013692A2 (pt)
ES (1) ES2957232T3 (pt)
IL (1) IL262664B (pt)
MX (1) MX2018015399A (pt)
PH (1) PH12018502618A1 (pt)
RU (1) RU2768875C2 (pt)
SG (1) SG11201809802PA (pt)
TW (1) TWI739850B (pt)
WO (1) WO2017217351A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3727383A1 (en) 2017-12-19 2020-10-28 Mitsubishi Tanabe Pharma Corporation Compositions and methods for treating or preventing vasomotor symptoms
CN113677334B (zh) * 2019-02-01 2024-04-09 马歇尔大学科研协会 瞬时受体电位melastatin 8(trpm8)拮抗剂和相关方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006122156A2 (en) * 2005-05-09 2006-11-16 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
WO2009073788A1 (en) 2007-12-07 2009-06-11 Firestone Leigh H Compositions and methods for treating menopausal females
CA2747637A1 (en) 2008-12-18 2010-07-15 Janssen Pharmaceutica Nv Sulfamides as trpm8 modulators
WO2010103381A1 (en) 2009-03-13 2010-09-16 Glenmark Pharmaceuticals S.A. Spirocyclic piperidine derivatives as trpm 8 modulators
EP2424517A4 (en) 2009-05-01 2013-01-23 Raqualia Pharma Inc SULFAMOYLBENZOIC ACID DERIVATIVES AS TRPM8 ANTAGONISTS
TW201103941A (en) 2009-06-10 2011-02-01 Janssen Pharmaceutica Nv Benzimidazole derivatives useful as TRPM8 channel modulators
EP2481727A1 (en) 2011-01-28 2012-08-01 Dompe S.p.A. TRPM8 receptor antagonists
PL2686302T3 (pl) * 2011-03-16 2017-01-31 Mitsubishi Tanabe Pharma Corporation Związki sulfonamidowe mające działanie antagonistyczne dla TRPMS
JP2014527511A (ja) 2011-06-24 2014-10-16 アムジエン・インコーポレーテツド Ｔｒｐｍ８拮抗剤及び治療におけるそれらの使用
DK2793883T3 (en) 2011-12-19 2018-07-30 Dompe Farm Spa TRPM8 antagonists
WO2014042238A1 (ja) * 2012-09-14 2014-03-20 田辺三菱製薬株式会社 スルホンアミド化合物
JP5985453B2 (ja) * 2012-09-14 2016-09-06 田辺三菱製薬株式会社 医薬組成物
JP6352413B2 (ja) * 2013-10-22 2018-07-04 エドワード タク ウェイＷＥＩ， Ｅｄｗａｒｄ Ｔａｋ 感覚的不快感の治療向け局所薬としてのジ−イソプロピル−アルカン（ｄａｐａ）化合物

Also Published As

Publication number Publication date
EP3468557A1 (en) 2019-04-17
WO2017217351A1 (en) 2017-12-21
AU2017285609B2 (en) 2022-08-18
IL262664B (en) 2021-10-31
CA3022808A1 (en) 2017-12-21
ES2957232T3 (es) 2024-01-15
PH12018502618A1 (en) 2019-10-07
CN113384577A (zh) 2021-09-14
CN113398124A (zh) 2021-09-17
MX2018015399A (es) 2019-04-29
CO2018013692A2 (es) 2019-01-18
JP6943887B2 (ja) 2021-10-06
IL262664A (en) 2018-12-31
SG11201809802PA (en) 2018-12-28
TWI739850B (zh) 2021-09-21
EP3468557B1 (en) 2023-07-26
US20210177830A1 (en) 2021-06-17
KR20190017800A (ko) 2019-02-20
US10993939B2 (en) 2021-05-04
AU2022211877A1 (en) 2022-09-01
RU2019100424A (ru) 2020-07-15
US20190142821A1 (en) 2019-05-16
JP2019517573A (ja) 2019-06-24
RU2768875C2 (ru) 2022-03-25
EP4140484A1 (en) 2023-03-01
RU2019100424A3 (pt) 2020-09-24
KR20230005413A (ko) 2023-01-09
AU2017285609A1 (en) 2019-01-03
TW201803595A (zh) 2018-02-01
CN114748624A (zh) 2022-07-15
CN109310689A (zh) 2019-02-05

Similar Documents

Publication Publication Date Title
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP18049420A (es) Composiciones novedosas, usos y métodos para hacerlas
BR112018073384A2 (pt) polinucleotídeos moduladores
BR112016025423A2 (pt) compostos e composições como agonistas de receptores do tipo toll 7
ECSP18060342A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
BR112018013530A2 (pt) ?peptídeo isolado, polinucleotídeo e composição farmacêutica?
BR112018007017A2 (pt) polipeptídeos
BR112017009497A2 (pt) polinucleotídeos de aadc para o tratamento da doença de parkinson
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
UY35916A (es) Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio
EA201692568A1 (ru) Составы с полипептидами-рецепторами и связанные с ними способы
EA201591661A1 (ru) Пептиды и композиции для лечения повреждений суставов
BR112016018062A8 (pt) compostos terapêuticos, composição farmacêutica e usos
BR112015016585A2 (pt) Compostos radiofarmacêuticos baseados em triazina, complexos de metal e composição farmacêutica compreendendo os referidos complexos
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
UY36178A (es) Novedosos derivados de ácido heteroaril-butanoico
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
BR112017001221A2 (pt) derivados de indolizina que são aplicáveis a doenças neurodegenerativas
CO2017001226A2 (es) Derivados de 6–alquinil–piridina como miméticos de smac
BR112017012581A2 (pt) tratamento de degeneração da retina com o uso de células progenitoras
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
CL2018001715A1 (es) Reguladores del cftr y métodos para su uso
BR112018075403A2 (pt) composições para tratar ou prevenir sintomas vasomotores

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]